Completa los detalles para desbloquear el seminario web

Nombre

Apellidos

Correo electrónico de la empresa

Empresa

Cargo

Número de teléfono

Al continuar, aceptas nuestros Términos de uso, nuestra Política de privacidad y que tus datos se almacenen en los EE. UU.

Comparte este seminario web

Cierra tu brecha de habilidades en datos e IA

Somos la única plataforma diseñada de forma única para impulsar las habilidades de datos e IA en toda tu organización. Exploremos un programa a medida.

Reserva Una Demo Para Empresas

¿Mejorando las habilidades de un equipo pequeño?Empieza hoy mismo

Artificial Intelligence

AI in Healthcare: What the Slope of Enlightenment Will Look Like

November 2021

Tu(s) presentador(es)

Hugo Bowne-Anderson

Data Scientist

Arnaub Chatterjee

Arnaub is a Senior Expert/Associate Partner in the Pharmaceutical and Medical Products group at McKinsey & Company. Additionally, he serves as Teaching Associate in the Department of Health Care Policy at Harvard Medical School and Lecturer in the Department of Policy Analysis and Management at Cornell University. At McKinsey, he advises pharmaceutical and biotech companies on a range of topics, including digital transformation, utilizing novel data and analytics for product positioning and preparing for launch. He also works with leading technology companies and startups who are entering the healthcare sector on a range of market strategy and entry issues.

Prior to McKinsey, he served as Director within Merck's Data Science and Insights group where he led ventures and partnerships with academic medical centers, payers and technology companies to power R&D and commercial activities. He previously served in the Obama Administration as an advisor to former Chief Technology Officers Todd Park and Bryan Sivak at the U.S. Department of Health and Human Services (HHS). At HHS, he co-led efforts for the Health Data Initiative, designed the www.healthdata.gov platform, and launched the Innovation Fellows Program. At HHS, he also worked in the Secretary's Office as a lead policy analyst on healthcare fraud and abuse policy initiatives around the Affordable Care Act. Prior to government service, he spent a number of years as a strategy consultant at Deloitte Consulting, supporting pharmaceutical companies on M&A strategy.

He holds graduate degrees in health administration (MHA) and public administration (MPA) from Cornell University and received his undergraduate degree from the University of Michigan.

Summary

Arnav Chatterjee, a senior vice president of product at Metadata Solutions, discussed the current and future state of AI in healthcare. The conversation revolved around the Gartner Hype Cycle, which maps out the development and adoption of technologies, specifically AI's role in healthcare. Arnav examined various sectors within healthcare, including pharma, clinical trials, and diagnostics, emphasizing how AI is transforming these areas. AI's potential in improving clinical operations, advancing drug discovery, and enhancing diagnostic imaging was highlighted. However, the conversation also discussed the ethical challenges, biases, and high expectations associated with AI integration in healthcare. Arnav stressed the need for managing expectations and ensuring ethical considerations are prioritized in AI deployment in healthcare. He also touched on the role of big tech companies in healthcare data and the crucial need for preserving patient privacy and addressing algorithmic biases.

Key Takeaways:

AI is significantly impacting sectors in healthcare, including pharma, drug discovery, and diagnostics.
The Gartner Hype Cycle aids in understanding the current stage of AI's development and adoption in healthcare.
Ethical challenges and biases remain a significant concern in the implementation of AI in healthcare.
There is a need for comprehensive data sets to build effective AI models.
Patient privacy and algorithmic transparency are vital in healthcare AI applications.

Deep Dives

AI in Pharma and Drug Discovery

The integration of AI in pharma and drug discovery indicates a significant advancement in how new medicines are developed. Arnav pointed out the challenges faced in late-stage clinical trials, where 50% fail due to ineffective drug targets, leading to only 15% of drugs achieving approval. AI-driven solutions aim to improve operations by predicting patient enrollment and optimizing drug design to enhance efficacy. He mentioned the potential of AI to reduce resource and time investment in drug discovery by understanding the optimal combinations of drug compounds. The use of AI in identifying novel drug targets is a promising area, as evidenced by AI's role in developing the first drug tested on humans for obsessive-compulsive disorder. However, the high expectations surrounding AI's capabilities must be managed, with a clear distinction made between genuine progress and overhyped achievements.

Diagnostic Imaging and AI

AI's role in diagnostic imaging has been a key part of its application in healthcare. Arnav discussed how AI algorithms have shown success in interpreting medical images, such as MRIs, CTs, and PET scans, which make up 90% of healthcare data. Google's work in diabetic retinopathy and breast cancer screening showcases AI's potential, with algorithms outperforming radiologists in terms of accuracy and reducing false positives and negatives. The conversation emphasized the need for linking imaging data with electronic medical records to derive meaningful outcomes. However, Arnav cautioned that while AI can assist in diagnostics, it cannot replace the detailed decision-making of physicians, emphasizing the need for AI to support rather than replace human expertise.

Ethical Challenges and Biases in AI

Ethical considerations and biases present significant challenges in the implementation of AI in healthcare. Arnav noted that biases in training data could lead to skewed algorithmic predictions, as demonstrated by a study revealing racial biases in healthcare algorithms. He stressed the need for recognizing and correcting these biases, which often stem from socioeconomic disparities. The conversation also addressed the importance of preserving patient privacy, with big tech companies' involvement in healthcare data causing concerns. Arnav highlighted initiatives like the European Commission's guidelines on trustworthy AI and the need for companies to adopt ethical AI principles. Transparency and accountability are key to ensuring AI benefits all patient groups equitably.

The Gartner Hype Cycle and AI Expectations

The Gartner Hype Cycle provides a framework for understanding the life cycle of AI technologies in healthcare. Arnav emphasized that while AI has reached the peak of high expectations, it is vital to manage these expectations to avoid disillusionment. AI's role is to enhance and assist healthcare processes, not replace human professionals. The conversation also touched on the economic aspects, with high investment levels contributing to high expectations of rapid returns. Arnav called for a realistic appreciation of AI's capabilities, acknowledging that drug discovery and healthcare improvements require time and careful validation. Recognizing the ongoing progress in AI-driven healthcare solutions, he encouraged stakeholders to focus on sustainable and ethical advancements.